PreMenstrual Dysphoric Disorder (PMDD) is a hormonal health condition that causes severe periodical mood and functioning disruptions, and disproportionately affects people with ADHD/Autism.

Premenstrual Dysphoric Disorder (PMDD) is a hormonal health condition that causes clinically significant and impairing depression, anxiety, mood swings, and physical symptoms in the week leading up to a period. PMDD symptoms improve during or following a period and are minimal, if not absent, in the following weeks. PMDD disproportionately affects people with Autism and ADHD.

Autism, ADHD, and PMDD

PMDD disproportionately affects people with ADHD and autism, with up to 92% of autistic women and 46% of women with ADHD experiencing PMDD, though estimates vary. There is no agreed-upon cause of PMDD, nor is it known why it affects certain populations more than others, though there are various theories. Possible explanations include:

PMDD Symptoms

To reach a PMDD diagnosis the symptoms below must periodically cause distress or interfere with daily activities. Note that PMDD is much more severe than PMS.

  • Unstable and easily influenced mood
  • Irritability, anger
  • Depression or hopelessness, suicidal ideation
  • Anxiety or tension
  • Decreased interest in usual activities
  • Self-critical thoughts, increased sensitivity to rejection
  • Difficulty concentrating
  • Fatigue, lethargy
  • Appetite changes
  • Sleep difficulties, either insomnia or hypersomnia
  • Feeling of overwhelm
  • Physical symptoms: breast tenderness, joint or muscle pain, a sensation of bloating, or weight gain

PMDD vs. PMS

While PMDD shares symptoms with premenstrual syndrome (PMS), PMDD is less common and more severe. PMS may occur in up to 48% of people who menstruate, while PMDD only occurs in 3 to 9%. In addition, PMDD symptoms interfere with daily functioning, and often requires accommodations. People with PMDD have an increased risk of developing suicidal ideation and studies suggest that it also negatively affects pain sensitivity . Some people who do not meet the criteria for PMDD may have severe PMS and benefit from similar treatment.

Treating PMDD

There are various options to treat PMDD. Some health practitioners will suggest selective serotonin reuptake inhibitors (SSRIs) or selective serotonin and norepinephrine reuptake inhibitors (SNRIs) to treat PMDD but these tend to be ineffective in autistics. Little research has been done on the effect of antidepressants on autistic women of reproductive age.

  • Menstrual neuromodulation therapy: This is a drug free and hormone free none-invasive innovative treatment targeting PMS and PMDD symptoms.
  • Contraceptives: Hormonal contraceptives regulate hormones and can alleviate both physical and psychiatric PMDD symptoms.
  • Cycle tracking: Increased menstrual awareness through astute tracking will allow the person to organise their lives to work with their cycles (e.g. avoidance of certain stressors and foods around the 21st day of your cycle)
  • Supplements: Vitamin B6, vitamin E, calcium, magnesium supplements etc. can help to support the body and ease PMDD symptoms.
  • Herbal remedies: Chasteberry, evening primrose oil, gingko and St. John’s wort can be used to manage PMDD naturally. Never mix St. John’s wort with SSRIs/SNRIs.

Additional sources:

Menstruation and menopause in autistic people 

Prevalence of Premenstrual Syndrome in Autism: A Prospective Observer-rated Study – H Obaydi, BK Puri, 2008 

The Etiology of Premenstral Dysphoric Disorder: 5 interwoven pieces. 

12 PMDD natural treatment options 

Epidemiology of Premenstrual Syndrome (PMS)-A Systematic Review and Meta-Analysis Study  

Nociceptive processing in women with premenstrual dysphoric disorder (PMDD): the role of menstrual phase and sex hormones 

The prevalence of early life trauma in premenstrual dysphoric disorder (PMDD)

How many people with PMDD also have ADHD or Autism? | IAPMD FAQ

SSRI Disappoints as Treatment for Common Autism Symptom | Psychiatric News 

Use of selective serotonin and norepinephrine reuptake inhibitors (SNRIs) in the treatment of autism spectrum disorder (ASD), comorbid psychiatric disorders and ASD-associated symptoms: a clinical review